{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:03:12Z","timestamp":1790229792851,"version":"4.1.0"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270648, 82203785"],"award-info":[{"award-number":["82270648, 82203785"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Chimeric antigen receptor (CAR)-T cell therapy has achieved remarkable success in hematologic malignancies, prompting its exploration in solid tumors. This systematic review and meta-analysis aimed to evaluate the safety and feasibility of CAR-T therapy for solid tumor treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Cochrane Library, Embase, and Web of Science from database inception to June 1, 2026, for clinical studies evaluating CAR-T therapy in solid tumors. Primary outcomes included the incidence of any-grade and grade \u22653 adverse events (AEs); secondary outcomes were the overall response rate (ORR) and disease control rate (DCR). This review adhered to PRISMA guidelines and was registered with PROSPERO (CRD42024549048).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>52 studies with 712 patients were enrolled in our study. Lymphopenia (70%, grade\u22653: 48%) was the most common adverse event. The pooled ORR and DCR were 13% (95%CI: 11-16%) and 63% (95%CI: 59-67%), respectively. Subgroup analysis indicated that the incidence of hematologic toxicity was significantly higher in patients who had received lymphodepletion, and intravenous delivery was associated with a higher risk of several AEs. Patients who had undergone lymphodepletion (LD) achieved higher ORR (p = 0.0002) and DCR (p = 0.0083). In comparison to regional delivery, intravenous infusion was associated with higher ORR (p = 0.0345).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CAR-T therapy demonstrates an acceptable safety profile for solid tumors. While lymphodepletion and intravenous delivery correlate with higher ORR and DCR, they also increase adverse event risks. Balancing therapeutic benefits and safety concerns therefore remains a critical consideration for clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1957437","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:44:45Z","timestamp":1790228685000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The safety and efficacy of chimeric antigen receptor-T cell therapy in solid malignancies: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Kunpeng","family":"Wang","sequence":"first","affiliation":[{"name":"Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangneng","family":"Yu","sequence":"additional","affiliation":[{"name":"Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinting","family":"Jiang","sequence":"additional","affiliation":[{"name":"Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhicheng","family":"Guo","sequence":"additional","affiliation":[{"name":"Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children of the Ministry of Education (MOE), West China Second University Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"Key Laboratory of Chronobiology, National Health Commission of China, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangliang","family":"Xu","sequence":"additional","affiliation":[{"name":"Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16081599","article-title":"Chimeric antigen receptor (CAR) T-cell therapy in hematologic Malignancies: Clinical implications and limitations","volume":"16","author":"Bl\u00fcm","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: Current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.abe2606","article-title":"Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function","volume":"14","author":"Salter","year":"2021","journal-title":"Sci Signal"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/356607a0","article-title":"CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones","volume":"356","author":"Harding","year":"1992","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-06-0160","article-title":"CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells","volume":"66","author":"Kowolik","year":"2006","journal-title":"Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003354","article-title":"4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells","volume":"9","author":"Roselli","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.09.021","article-title":"Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development","volume":"31","author":"Tang","year":"2023","journal-title":"Mol Ther"},{"key":"B8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"508","DOI":"10.21037\/atm-21-5019","article-title":"The efficacy and safety of chimeric antigen receptor T cells in digestive system cancers: A systematic review and meta-analysis","volume":"10","author":"Zhao","year":"2022","journal-title":"Ann Transl Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3425291","article-title":"Efficiency of CAR-T therapy for treatment of solid tumor in clinical trials: A meta-analysis","volume":"2019","author":"Hou","year":"2019","journal-title":"Dis Markers"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): Development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"Anz J Surg"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Bmj"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for relapsed or refractory high-risk neuroblastoma","volume":"388","author":"Del Bufalo","year":"2023","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: Phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-21-0407","article-title":"A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with Malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.05.012","article-title":"CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma","volume":"25","author":"Heczey","year":"2017","journal-title":"Mol Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.07.015","article-title":"Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers","volume":"27","author":"Haas","year":"2019","journal-title":"Mol Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02314","article-title":"Safety and efficacy of CT041 in patients with refractory metastatic pancreatic cancer: a pooled analysis of two early-phase trials","volume":"42","author":"Qi","year":"2024","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-01090","article-title":"Guanylyl cyclase 2C-targeted chimeric antigen receptor T-cell therapy in patients with metastatic colorectal cancer","volume":"44","author":"Qi","year":"2026","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: A phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-354449","article-title":"Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma","volume":"118","author":"Louis","year":"2011","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"eadg9721","DOI":"10.1126\/sciadv.adg9721","article-title":"EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors","volume":"9","author":"Li","year":"2023","journal-title":"Sci Adv"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O'Rourke","year":"2017","journal-title":"Sci Transl Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2020.1846926","article-title":"Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: A single-arm, open-label, phase II trial","volume":"9","author":"Dai","year":"2020","journal-title":"Oncoimmunology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2034-7","article-title":"The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity","volume":"66","author":"Thistlethwaite","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02019","article-title":"Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors","volume":"2024","author":"Lin","year":"2024","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","article-title":"Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial","volume":"155","author":"Beatty","year":"2018","journal-title":"Gastroenterology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-17-0189","article-title":"Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer","volume":"5","author":"Tchou","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaf064","article-title":"Locoregional infusion of EGFR806-CAR T cells for recurrent or refractory pediatric CNS tumors: Results of the completed BrainChild02 phase 1 clinical trial","volume":"27","author":"Gust","year":"2025","journal-title":"Neuro Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mt.6300104","article-title":"Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma","volume":"15","author":"Park","year":"2007","journal-title":"Mol Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-016-5023-8","article-title":"Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed\/refractory non-small cell lung cancer","volume":"59","author":"Feng","year":"2016","journal-title":"Sci China Life Sci"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13238-017-0440-4","article-title":"Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers","volume":"9","author":"Feng","year":"2017","journal-title":"Protein Cell"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03839-5","article-title":"GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and\/or recurrent neuroblastoma in pediatric patients","volume":"148","author":"Yu","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02612-0","article-title":"CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: The phase 1 BNT211-01 trial","volume":"29","author":"Mackensen","year":"2023","journal-title":"Nat Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00749-6","article-title":"Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial","volume":"5","author":"Hegde","year":"2024","journal-title":"Nat Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102302","article-title":"Chlorotoxin-directed CAR T cell therapy for recurrent glioblastoma: Interim clinical experience demonstrating feasibility and safety","volume":"6","author":"Barish","year":"2025","journal-title":"Cell Rep Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0184","article-title":"HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: A phase 1 dose-escalation trial","volume":"3","author":"Ahmed","year":"2017","journal-title":"JAMA Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.3891","article-title":"Chimeric antigen receptor T cells targeting CD19 and GCC in metastatic colorectal cancer","volume":"10","author":"Chen","year":"2024","journal-title":"JAMA Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02229","article-title":"STRIvE-02: A first-in-human phase I study of systemically administered B7-H3 chimeric antigen receptor T cells for patients with relapsed\/refractory solid tumors","volume":"42","author":"Pinto","year":"2024","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03451-3","article-title":"Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: A phase 1 trial","volume":"31","author":"Vitanza","year":"2025","journal-title":"Nat Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-22-0750","article-title":"Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: Preliminary first-in-human bioactivity and safety","volume":"13","author":"Vitanza","year":"2023","journal-title":"Cancer Discov"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.Crc-22-0486","article-title":"Phase I trial of autologous RNA-electroporated cMET-directed CAR T cells administered intravenously in patients with melanoma and breast carcinoma","volume":"3","author":"Shah","year":"2023","journal-title":"Cancer Res Commun"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102175","article-title":"RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: A phase I trial","volume":"63","author":"Fu","year":"2023","journal-title":"eClinicalMedicine"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23214","article-title":"Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: Possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response","volume":"76","author":"Junghans","year":"2016","journal-title":"Prostate"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007162","article-title":"Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study","volume":"11","author":"Papa","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"10743","DOI":"10.1038\/s41467-024-53220-6","article-title":"PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: A phase 1 dose escalation trial","volume":"15","author":"Stein","year":"2024","journal-title":"Nat Commun"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000260","article-title":"Pilot trial of adoptive transfer of chimeric antigen receptor-transduced T cells targeting EGFRvIII in patients with glioblastoma","volume":"42","author":"Goff","year":"2019","journal-title":"J Immunother"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03745-0","article-title":"Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13R\u03b12 in recurrent glioblastoma: A phase 1 trial","volume":"31","author":"Bagley","year":"2025","journal-title":"Nat Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1421","article-title":"Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases","volume":"21","author":"Katz","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-019-0104-z","article-title":"HITM-SIR: Phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA(+) liver metastases","volume":"27","author":"Katz","year":"2020","journal-title":"Cancer Gene Ther"},{"key":"B53","doi-asserted-by":"publisher","first-page":"OF1","DOI":"10.1158\/2159-8290.CD-24-0102","article-title":"CD70-targeted allogeneic CAR T-cell therapy for advanced clear cell renal cell carcinoma","volume":"14","author":"Pal","year":"2024","journal-title":"Cancer Discov"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-25-3052","article-title":"Phase 1 trial of P-PSMA-101 CAR-T cells in patients with metastatic castration resistant prostate cancer (mCRPC)","volume":"32","author":"Slovin","year":"2026","journal-title":"Clin Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02979-8","article-title":"PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: A phase 1 trial","volume":"30","author":"Dorff","year":"2024","journal-title":"Nat Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008659","article-title":"Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers","volume":"12","author":"Gargett","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101125","article-title":"Cellular and molecular mechanisms of gastrointestinal cancer liver metastases and drug resistance","volume":"77","author":"Dong","year":"2024","journal-title":"Drug Resist Update"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: A phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03613-7","article-title":"Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed\/refractory non-small cell lung cancer patients","volume":"147","author":"Zhang","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-026-01124-3","article-title":"Hypoxia-responsive CEA-targeted CAR T cells in CEA-positive solid tumors through intraperitoneal or intravenous infusion: A phase 1 trial","volume":"7","author":"Gao","year":"2026","journal-title":"Nat Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01711-9","article-title":"Safety and antitumor activity of GD2-specific 4SCAR-T cells in patients with glioblastoma","volume":"22","author":"Liu","year":"2023","journal-title":"Mol Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-17-0432","article-title":"Phase I Study of Chimeric Antigen Receptor-Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers","volume":"24","author":"Guo","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.cpt.2025.12.002","article-title":"Safety and efficacy of JWATM204, a novel Glypican-3 (GPC3)-targeted CAR T cell therapy for advanced hepatocellular carcinoma: A phase I dose-escalation study","volume":"4","author":"Yang","year":"2026","journal-title":"Cancer Pathog Ther"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2020.04.088","article-title":"Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: a phase I clinical trial","volume":"22","author":"Liu","year":"2020","journal-title":"Cytotherapy"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.03.010","article-title":"Phase I escalating-dose trial of CAR-T therapy targeting CEA+ metastatic colorectal cancers","volume":"25","author":"Zhang","year":"2017","journal-title":"Mol Ther"},{"key":"B66","year":"2009"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"B69","doi-asserted-by":"publisher","first-page":"224ra225","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.06.025","article-title":"Reactive myelopoiesis triggered by lymphodepleting chemotherapy limits the efficacy of adoptive T cell therapy","volume":"28","author":"Innamarato","year":"2020","journal-title":"Mol Ther"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.jpainsymman.2020.10.017","article-title":"Subjective toxicity profiles of children in treatment for cancer: a new guide to supportive care","volume":"61","author":"Hinds","year":"2021","journal-title":"J Pain Symptom Manage"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J Exp Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"key":"B75","doi-asserted-by":"publisher","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci Transl Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.04.006","article-title":"Regional CAR T cell therapy: An ignition key for systemic immunity in solid tumors","volume":"40","author":"Cherkassky","year":"2022","journal-title":"Cancer Cell"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0066844","article-title":"Systematic review of the empirical evidence of study publication bias and outcome reporting bias - an updated review","volume":"8","author":"Dwan","year":"2013","journal-title":"PloS One"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1957437\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:44:46Z","timestamp":1790228686000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1957437\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":77,"alternative-id":["10.3389\/fimmu.2026.1957437"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1957437","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"article-number":"1957437"}}